GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Durata Therapeutics Inc (FRA:DTA) » Definitions » Cash Receipts from Fees and Commissions

Durata Therapeutics (FRA:DTA) Cash Receipts from Fees and Commissions


View and export this data going back to . Start your Free Trial

What is Durata Therapeutics Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


Durata Therapeutics (FRA:DTA) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.